- Home
- SSSS vs STTK Comparison
SSSS vs STTK Comparison
Compare SSSS & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSSS
- STTK
- Stock Information
- Founded
- SSSS 2010
- STTK 2016
- Country
- SSSS United States
- STTK United States
- Employees
- SSSS N/A
- STTK N/A
- Industry
- SSSS Finance: Consumer Services
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- SSSS Finance
- STTK Health Care
- Exchange
- SSSS Nasdaq
- STTK Nasdaq
- Market Cap
- SSSS 138.2M
- STTK 112.6M
- IPO Year
- SSSS N/A
- STTK 2020
- Fundamental
- Price
- SSSS $9.98
- STTK $2.56
- Analyst Decision
- SSSS Strong Buy
- STTK Hold
- Analyst Count
- SSSS 4
- STTK 6
- Target Price
- SSSS $9.50
- STTK $2.67
- AVG Volume (30 Days)
- SSSS 186.1K
- STTK 548.5K
- Earning Date
- SSSS 11-06-2025
- STTK 11-13-2025
- Dividend Yield
- SSSS 10.67%
- STTK N/A
- EPS Growth
- SSSS N/A
- STTK N/A
- EPS
- SSSS 2.22
- STTK N/A
- Revenue
- SSSS $2,784,381.00
- STTK $2,997,000.00
- Revenue This Year
- SSSS $7,183.09
- STTK N/A
- Revenue Next Year
- SSSS N/A
- STTK N/A
- P/E Ratio
- SSSS $4.22
- STTK N/A
- Revenue Growth
- SSSS N/A
- STTK N/A
- 52 Week Low
- SSSS $3.87
- STTK $0.69
- 52 Week High
- SSSS $9.50
- STTK $2.49
- Technical
- Relative Strength Index (RSI)
- SSSS 74.65
- STTK 70.47
- Support Level
- SSSS $8.75
- STTK $2.29
- Resistance Level
- SSSS $9.40
- STTK $2.49
- Average True Range (ATR)
- SSSS 0.25
- STTK 0.21
- MACD
- SSSS 0.05
- STTK -0.02
- Stochastic Oscillator
- SSSS 99.05
- STTK 87.82
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.